{"title":"前列腺癌超低分割放疗后的生活质量:RTOG 0938试验的挑战","authors":"S. Arcangeli, V. Pinzi","doi":"10.21037/tro.2019.02.01","DOIUrl":null,"url":null,"abstract":"In the Red Journal , Lukka and colleagues reported optimal quality of life (QoL) outcomes of the NRG Oncology RTOG 0938 trial (1). This trial randomly compared two short radiation schedules of 5 and 12 fractions of 7.25 and 4.3 Gy each, respectively, for the treatment of localized, low risk prostate cancer. The primary endpoint was the proportion of patients with a change in bowel and urinary EPIC-50 score at 1-year.","PeriodicalId":93236,"journal":{"name":"Therapeutic radiology and oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21037/tro.2019.02.01","citationCount":"0","resultStr":"{\"title\":\"Quality of life after ultra-hypofractionated radiotherapy for prostate cancer: the challenge of RTOG 0938 trial\",\"authors\":\"S. Arcangeli, V. Pinzi\",\"doi\":\"10.21037/tro.2019.02.01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the Red Journal , Lukka and colleagues reported optimal quality of life (QoL) outcomes of the NRG Oncology RTOG 0938 trial (1). This trial randomly compared two short radiation schedules of 5 and 12 fractions of 7.25 and 4.3 Gy each, respectively, for the treatment of localized, low risk prostate cancer. The primary endpoint was the proportion of patients with a change in bowel and urinary EPIC-50 score at 1-year.\",\"PeriodicalId\":93236,\"journal\":{\"name\":\"Therapeutic radiology and oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-02-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.21037/tro.2019.02.01\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic radiology and oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/tro.2019.02.01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic radiology and oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/tro.2019.02.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Quality of life after ultra-hypofractionated radiotherapy for prostate cancer: the challenge of RTOG 0938 trial
In the Red Journal , Lukka and colleagues reported optimal quality of life (QoL) outcomes of the NRG Oncology RTOG 0938 trial (1). This trial randomly compared two short radiation schedules of 5 and 12 fractions of 7.25 and 4.3 Gy each, respectively, for the treatment of localized, low risk prostate cancer. The primary endpoint was the proportion of patients with a change in bowel and urinary EPIC-50 score at 1-year.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
